Supernus Pharmaceuticals (SUPN) Research & Development (2016 - 2025)
Historic Research & Development for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $29.4 million.
- Supernus Pharmaceuticals' Research & Development rose 113.65% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.1 million, marking a year-over-year increase of 343.88%. This contributed to the annual value of $108.8 million for FY2024, which is 1878.2% up from last year.
- Per Supernus Pharmaceuticals' latest filing, its Research & Development stood at $29.4 million for Q3 2025, which was up 113.65% from $22.1 million recorded in Q2 2025.
- In the past 5 years, Supernus Pharmaceuticals' Research & Development registered a high of $34.3 million during Q1 2021, and its lowest value of $15.5 million during Q2 2021.
- In the last 5 years, Supernus Pharmaceuticals' Research & Development had a median value of $22.7 million in 2023 and averaged $23.4 million.
- As far as peak fluctuations go, Supernus Pharmaceuticals' Research & Development skyrocketed by 8102.13% in 2021, and later crashed by 3920.95% in 2022.
- Supernus Pharmaceuticals' Research & Development (Quarter) stood at $21.1 million in 2021, then fell by 15.68% to $17.8 million in 2022, then soared by 31.35% to $23.3 million in 2023, then increased by 22.7% to $28.6 million in 2024, then grew by 2.51% to $29.4 million in 2025.
- Its Research & Development stands at $29.4 million for Q3 2025, versus $22.1 million for Q2 2025 and $26.9 million for Q1 2025.